Results · Apr-Jun 2026
Parmax Pharma Q1 FY27 results
Sales grew 323% to ₹8.2 crore from ₹1.9 crore in Apr-Jun 2025.
Operating profit was ₹0.83 crore, an operating margin of 10.1% (up 22.9 points from a year ago).
Net profit turned positive: ₹2.2 crore against a loss of ₹0.76 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +148%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 8.2 | 1.9 | +323% |
| Operating profit (EBITDA) | 0.8 | -0.2 | n/m |
| Operating margin | 10.1% | −12.9% | +22.9 pts |
| Net profit | 2.2 | -0.8 | turns positive |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.